CareersPipelineCollaboration RareInnovation SVGOMG The best SVG optimizer and minifier Open SVG Paste markup Demo Contribute SVGOMG provides you several options to clean and compress your SVG files. Clean up, remove, merge, minify. Upload or copy the source of your SVG to get started! 947 bytes → 267 bytes 28.19% Finance peopleAdvance treatment Skip to main contentSkip to navigationSkip to search
HNSA   ( ,  %) SEK
Quotes are delayed 15 minutes

Increase of number of shares and votes in Hansa Medical AB (publ)

29 Dec 2017, 08:00
Regulatory information
As previously announced, the general meeting of Hansa Medical AB (publ) has, on December 22, 2017, resolved on a share issue of 2,752,526 ordinary shares. The company’s registered share capital and number of outstanding shares and votes have thus increased during December.

As of December 29, 2017, the total number of registered and outstanding shares of Hansa Medical amounts to 38,208,386 of which 37,807,386 are ordinary shares and 401.000 are C shares. As of December 29, 2017, the number of votes in Hansa Medical amounts to 37,847,486 and the registered share capital amounts to SEK 38,208,386.

This information is information that Hansa Medical AB (publ) is obliged to make public pursuant to the Financial Instruments Trading Act. The information was submitted for publication at 08:00 CET on December 29, 2017.

Files

For further information, please contact:
Emanuel Björne, Vice President Business Development and Investor Relations, Hansa Medical AB (publ)
Mobile: 46707175477
E-mail: emanuel.bjorne@hansamedical.com

About Hansa Medical AB
Hansa Medical is a biopharmaceutical company developing novel immunomodulatory enzymes for transplantation and acute autoimmune diseases. The lead product, IdeS, is a proprietary antibody-degrading enzyme currently in late- stage clinical development for kidney transplant patients, with significant potential for further development in other solid organ transplants and in acute autoimmune indications. The company also has a strong pipeline of preclinical projects that may provide a second wave of potential drugs. Under the project name NiceR, novel immunoglobulin cleaving enzymes are developed for repeat dosing with the objective of treating relapsing autoimmune diseases and cancer. Hansa Medical is based in Lund, Sweden, its shares (ticker: HMED) are listed on Nasdaq Stockholm.